Volume 17, Issue 67 (8-2009)                   J Adv Med Biomed Res 2009, 17(67): 11-22 | Back to browse issues page

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Ghahremani Z, Rezaee- Kalaj S, Zarrindast M R, Jahanguiri B, jafari M R. Interaction between JWH133-induced Antinociception and two extreme Doses of Celecoxib. J Adv Med Biomed Res 2009; 17 (67) :11-22
URL: http://journal.zums.ac.ir/article-1-951-en.html
1- Dept. of Physiology and Pharmacology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran.
2- Dept. of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
3- Dept. of Physiology and Pharmacology, School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran. , jafarimrj@yahoo.com
Abstract:   (172936 Views)

Background and Objective: JWH133 is known to have cannabinoid-2 (CB2) receptor agonist properties. Celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is also known to have antinociceptive properties. Endocannabinoids produce analgesia possibly through cyclooxygenase (COX) pathway. The aim of the present work was: to study the effect of celecoxib on JWH133 induced antinociception and to compare the effects of two different dose ranges of celecoxib (mg/kg and nano g/kg) on the JWH133 antiniciceptive effect. Materials and Methods: We have studied the possible interaction of administration of mg/kg (50-200 mg/kg) and Ultra-Low Dose (ULD) (25 and 50 ng/kg) of celecoxib on the antinociceptive effect of intraperitoneal (i.p.) injection of JWH133 using formalin test in mice. Results: JWH133 (0.01, 0.1 and 1 mg/kg) induced antinociceptive effect just in phase I of the formalin test. Celecoxib (50-200 mg/kg) and its ULD (25 and 50 ng/kg) attenuated and potentiated, JWH133 induced antinociception, respectively. Conclusions: It is concluded that JWH-133 induced antinociception is modulated by celecoxib and mg/kg doses of celecoxib showed opposite effects compare to its ultra-low doses.

Full-Text [PDF 292 kb]   (160245 Downloads)    
Type of Study: Original Research Article |
Received: 2009/10/22 | Accepted: 2014/06/26 | Published: 2014/06/26

Send email to the article author


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Advances in Medical and Biomedical Research

Designed & Developed by : Yektaweb